United StatesÚltimas notícias

Zevra Therapeutics (NASDAQ:ZVRA) reported positive data for MIPLYFFA (arimoclomol) from a phase 2/3 open-label pediatric substudy in infants with Niemann-Pick disease type C.

President Donald Trump said funds released to Iran from frozen accounts will be "controlled by the U.S.A." and only to be used to purchase food and medical supplies from the US. Trump made the statement in a post on Truth Social on Tuesday. Tyler Kendall reports on Bloomberg Television.

Shopify (NYSE:SHOP) plans to ban all vape product sales from its e-commerce platform as early as this week, following pressure from U.S. state attorneys general.

Oracle (NYSE:ORCL) cut about 21,000 full-time jobs over the past year while accelerating its investment in AI data center infrastructure.

Meta (NASDAQ:META) launched a new line of AI-powered smart glasses called Meta Glasses, priced from $299 and designed in-house while still working in partnership with EssilorLuxottica.

Trinity Biotech (NASDAQ:TRIB) launched Trinovium, a subsidiary dedicated to advanced liquid cooling fluids and intelligence systems for AI and high-performance computing data centers.

Micron Technology (NASDAQ:MU) announced a strategic agreement with Anthropic that includes a memory and storage supply deal, technical collaboration on AI infrastructure, and a strategic investment in Anthropic’s Series H funding round.

"If you want to be longer risk, you can't wait too long," says Kate Moore, CIO at Citi Wealth, as she sees market pullbacks creating an opportunity to deploy capital during inflationary periods.

Revolution Medicines (NASDAQ:RVMD) began dosing patients in its global Phase 3 RASolute 305 trial for metastatic pancreatic cancer.

Allergan Aesthetics (NYSE:ABBV) received Health Canada approval for Boey (trenibotulinumtoxinE) to temporarily improve the appearance of moderate to severe glabellar (frown) lines in adults.

Fortitude Mining Holdings and HeartSciences (NASDAQ:HSCS) have entered into a definitive merger agreement to combine in an all-stock transaction expected to close in the second half of 2026.

Gilead Sciences (NASDAQ:GILD) announced that the European Commission has granted marketing authorization for Trodelvy (sacituzumab govitecan-hziy) as monotherapy for adult patients with unresectable or metastatic triple-negative breast cancer who have not received prior systemic therapy and are not candidates for PD-1 or PD-L1 inhibitor treatment.